RAPT Therapeutics, Inc. (RAPT) Accumulated Depreciation & Amortization (2020 - 2024)
RAPT Therapeutics' Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $9.8 million for Q3 2024.
- For Q3 2024, Accumulated Depreciation & Amortization changed N/A year-over-year to $9.8 million; the TTM value through Sep 2024 reached $9.8 million, changed N/A, while the annual FY2023 figure was $9.4 million, 13.55% up from the prior year.
- Accumulated Depreciation & Amortization for Q3 2024 was $9.8 million at RAPT Therapeutics, up from $9.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $9.8 million in Q3 2024 and bottomed at $6.3 million in Q1 2020.
- The 5-year median for Accumulated Depreciation & Amortization is $7.8 million (2021), against an average of $8.1 million.
- The largest annual shift saw Accumulated Depreciation & Amortization rose 17.64% in 2021 before it grew 7.35% in 2022.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $7.1 million in 2020, then increased by 8.5% to $7.7 million in 2021, then rose by 7.35% to $8.2 million in 2022, then increased by 13.55% to $9.4 million in 2023, then grew by 4.57% to $9.8 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Accumulated Depreciation & Amortization are $9.8 million (Q3 2024), $9.7 million (Q1 2024), and $9.4 million (Q4 2023).